HealthTree Logo HealthTree Foundation
Donate

Notifications

You're all caught up

HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

BETA - How is GPRC5D being targeted in myeloma?

Posted by
HealthTree Logo HealthTree
• June 9, 2026

Description

BETA - How is GPRC5D being targeted in myeloma?

On this video

Healthtree contact Ajai Chari, MD, Specialist

Ajai Chari, MD, Specialist

UCSF Helen Diller Family Comprehensive Cancer Center

Related Content

  • Event Navigating CAR-T Therapy: Understanding Side Effects and Staying Informed
  • Video BCMA Bispecifics in Myeloma: Do Real-World Results Match Clinical Trials? | IMS 2026
  • Video Cilta-Cel CAR-T for Myeloma: Which Patients Benefit From Earlier Treatment? | IMS 2026
  • Event Targeted and Immunologic Treatments for AML
  • Video Outpatient Bispecifics: Keeping Myeloma Patients Out of the Hospital | IMS 2026 #myeloma
  • Video MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026